Your browser doesn't support javascript.
loading
Antiviral Efficacy Testing of a Rechargeable Textile.
Izadjoo, Mina; Carhart, Kylin; Marcel, Vanessa; Izadjoo, Salman; Swicegood, Faith; Merritt, Casey; Clarke, Geroge.
Afiliación
  • Izadjoo M; Integrated Pharma Services, Rockville, MD 20850, USA.
  • Carhart K; Integrated Pharma Services, Rockville, MD 20850, USA.
  • Marcel V; Integrated Pharma Services, Rockville, MD 20850, USA.
  • Izadjoo S; Integrated Pharma Services, Rockville, MD 20850, USA.
  • Swicegood F; Integrated Pharma Services, Rockville, MD 20850, USA.
  • Merritt C; Integrated Pharma Services, Rockville, MD 20850, USA.
  • Clarke G; UMF Corporation, Skokie, IL 60076, USA.
Mil Med ; 189(Suppl 3): 525-529, 2024 Aug 19.
Article en En | MEDLINE | ID: mdl-39160886
ABSTRACT

INTRODUCTION:

In light of the COVID-19 (Coronovirus Disease 2019) pandemic, the use of personal protective equipment has become essential to reduce viral transmission and maintain public health. Viruses, particularly human coronavirus and influenza, pose significant challenges because of their various transmission routes. UMF Corporation's innovation, Micrillon, aims to address these challenges by creating durable, antiviral technology for textiles without harmful chemicals, reducing viral transmission risks. MATERIALS AND

METHODS:

The study followed ISO Standard 181842019, testing Micrillon textiles against Human Coronavirus OC43 and H1N1 Influenza A virus using MDCK and HCT-8 cell lines. Cell propagation, viral application, TCID50 (Median Tissue Culture Infectious Dose) testing, and maintenance protocols were rigorously implemented to assess antiviral efficacy.

RESULTS:

Micrillon gloves, fabrics, and fibers exhibited high antiviral efficacy against both viruses across various contact times. Gloves demonstrated exceptional antiviral activity against H1N1 (99.88%) and OC43 (99.67%) at 120 minutes. Rolled fabrics showed strong efficacy against H1N1 (99.42% at 30 minutes) and OC43 (>97%) at all time points. Bundled fibers displayed substantial efficacy against H1N1 (99.17% at 120 minutes) and OC43 (>98%) at all time points.

CONCLUSIONS:

The study demonstrates that Micrillon technology effectively inhibits viral activity, particularly in gloves, fabrics, and fibers. The innovation not only shows high antiviral efficacy against both Human Coronavirus and Influenza but also promises a reusable, sustainable solution, mitigating environmental impact and reducing the use of harmful chemicals in personal protective equipment. The technology holds promise for widespread use in health care and hospitality, offering a layer of protection while being environmentally conscious. Further development of such technologies can significantly reduce infection risks while minimizing environmental harm.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Antivirales / Textiles / Subtipo H1N1 del Virus de la Influenza A / COVID-19 Límite: Animals / Humans Idioma: En Revista: Mil Med Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Antivirales / Textiles / Subtipo H1N1 del Virus de la Influenza A / COVID-19 Límite: Animals / Humans Idioma: En Revista: Mil Med Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos